Patient Satisfaction and Clinical Experience With the Tandem t:slim X2 With Control-IQ Technology Advanced Hybrid Closed-Loop Insulin Delivery System

Q3 Medicine

Diabetes Spectrum Pub Date : 2024-07-05 DOI:10.2337/ds23-0057

Lisa T. Meade, Adriane B. Marino, Madison A. Barrier, Madison H. Wilson

{"title":"Patient Satisfaction and Clinical Experience With the Tandem t:slim X2 With Control-IQ Technology Advanced Hybrid Closed-Loop Insulin Delivery System","authors":"Lisa T. Meade, Adriane B. Marino, Madison A. Barrier, Madison H. Wilson","doi":"10.2337/ds23-0057","DOIUrl":null,"url":null,"abstract":"\n \n The purpose of this study was to assess patient satisfaction and clinical experience with the t:slim X2 with Control-IQ Technology automated insulin delivery system.\n \n \n \n This descriptive study used a retrospective electronic health record review of all individuals trained on the Control-IQ system between December 2019 and April 2022 in one adult endocrinology practice. A total of 99 patients using the Control-IQ system for at least 3 months completed the glucose monitoring satisfaction survey (GMSS). The primary outcome was overall satisfaction with the system as measured by the GMSS. Secondary outcomes included changes in A1C from baseline at 3, 6, and 12 months, the association between GMSS scores and A1C levels, and the use of the system’s sleep activity feature to achieve lower A1C levels.\n \n \n \n The overall satisfaction score for patients using the system was 4.0 ± 0.6 (possible score range 1–5). A1C decreased by 0.6% 3 months, 0.7% at 6 months, and 0.8% at 12 months. Participants with A1C levels ≤7% did not experience greater satisfaction compared to those with higher A1C levels.\n \n \n \n Participants using the Control-IQ system reported a high rate of overall satisfaction and experienced significant reductions from baseline A1C at 3, 6, and 12 months.\n","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Spectrum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2337/ds23-0057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The purpose of this study was to assess patient satisfaction and clinical experience with the t:slim X2 with Control-IQ Technology automated insulin delivery system. This descriptive study used a retrospective electronic health record review of all individuals trained on the Control-IQ system between December 2019 and April 2022 in one adult endocrinology practice. A total of 99 patients using the Control-IQ system for at least 3 months completed the glucose monitoring satisfaction survey (GMSS). The primary outcome was overall satisfaction with the system as measured by the GMSS. Secondary outcomes included changes in A1C from baseline at 3, 6, and 12 months, the association between GMSS scores and A1C levels, and the use of the system’s sleep activity feature to achieve lower A1C levels. The overall satisfaction score for patients using the system was 4.0 ± 0.6 (possible score range 1–5). A1C decreased by 0.6% 3 months, 0.7% at 6 months, and 0.8% at 12 months. Participants with A1C levels ≤7% did not experience greater satisfaction compared to those with higher A1C levels. Participants using the Control-IQ system reported a high rate of overall satisfaction and experienced significant reductions from baseline A1C at 3, 6, and 12 months.

查看原文本刊更多论文

采用 Control-IQ 技术的 Tandem t:slim X2 高级混合闭环胰岛素输送系统的患者满意度和临床体验

本研究旨在评估患者对带有 Control-IQ 技术的 t:slim X2 胰岛素自动给药系统的满意度和临床经验。这项描述性研究采用回顾性电子健康记录审查的方式，对一家成人内分泌科诊所在 2019 年 12 月至 2022 年 4 月期间接受过 Control-IQ 系统培训的所有人员进行了审查。共有 99 名使用 Control-IQ 系统至少 3 个月的患者完成了血糖监测满意度调查 (GMSS)。主要结果是通过 GMSS 测定的对该系统的总体满意度。次要结果包括 3 个月、6 个月和 12 个月时 A1C 与基线相比的变化、GMSS 分数与 A1C 水平之间的关联，以及使用该系统的睡眠活动功能达到较低 A1C 水平的情况。使用该系统的患者总体满意度为 4.0 ± 0.6（评分范围为 1-5）。3 个月后，A1C 下降了 0.6%，6 个月后下降了 0.7%，12 个月后下降了 0.8%。与 A1C 水平较高的参与者相比，A1C 水平≤7% 的参与者并没有获得更高的满意度。使用 Control-IQ 系统的参与者总体满意度较高，3 个月、6 个月和 12 个月时的 A1C 与基线相比均有显著下降。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes Spectrum Medicine-Internal Medicine

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： The mission of Diabetes Spectrum: From Research to Practice is to assist health care professionals in the development of strategies to individualize treatment and diabetes self-management education for improved quality of life and diabetes control. These goals are achieved by presenting review as well as original, peer-reviewed articles on topics in clinical diabetes management, professional and patient education, nutrition, behavioral science and counseling, educational program development, and advocacy. In each issue, the FROM RESEARCH TO PRACTICE section explores, in depth, a diabetes care topic and provides practical application of current research findings.